CBLB and lung carcinoma: PD-1/LAG-3 molecular mechanism of co-signaling was identified in T-cells, and combination of CBL-B inhibitors with anti-PD-1/anti-LAG-3 immunotherapies overcame PD-1/LAG-3-mediated resistance in models of lung cancer refractory to immunotherapies.